Cost-effectiveness of migraine treatment: a commentary.
Smith
Dean G
DG
Department of Health Management, University of Michigan, Ann Arbor, MI 48109-2029, USA. deans@umich.edu
D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D007211:Indoles / Q000191:economics / Q000627:therapeutic use; D008329:Managed Care Programs / Q000191:economics; D008881:Migraine Disorders / Q000188:drug therapy* / Q000191:economics; D009520:New Zealand; D011759:Pyrrolidines / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D017366:Serotonin Receptor Agonists / Q000191:economics / Q000627:therapeutic use; D018170:Sumatriptan / Q000191:economics / Q000627:therapeutic use; D014363:Tryptamines; D014662:Vasoconstrictor Agents / Q000191:economics / Q000627:therapeutic use
D007211:Indoles; D011759:Pyrrolidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C115647:eletriptan; D018170:Sumatriptan